Literature DB >> 18535199

Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.

David H Chang1, Haiteng Deng, Phillip Matthews, Joseph Krasovsky, Govind Ragupathi, Radek Spisek, Amitabha Mazumder, David H Vesole, Sundar Jagannath, Madhav V Dhodapkar.   

Abstract

CD1d-restricted T cells have been implicated in the pathogenesis of several chronic inflammatory states. However, the nature of the specific ligands recognized by these cells in vivo in patients with inflammatory or malignant diseases remains unknown. We took a biochemical approach to directly isolate and characterize the nature of CD1d-binding ligands from the plasma of myeloma patients. Characterization of these ligands revealed several lysophosphatidylcholine (LPC) species. Human LPC-CD1d dimer binding cells are T-cell receptoralphabeta(+) T cells but predominantly Valpha24(-)Vbeta11(-). Cytokine secretion by LPC-specific T cells is skewed toward IL-13 secretion, and the frequencies of these cells are increased in myeloma patients relative to healthy donors. These data identify a distinct population of human CD1d-restricted T cells specific for inflammation-associated lysolipids and suggest a novel mechanism for inflammation mediated immune regulation in human cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18535199      PMCID: PMC2515141          DOI: 10.1182/blood-2008-04-149831

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  NKT cells: T lymphocytes with innate effector functions.

Authors:  Luc Van Kaer
Journal:  Curr Opin Immunol       Date:  2007-04-10       Impact factor: 7.486

Review 2.  CD1d ligands: the good, the bad, and the ugly.

Authors:  Randy R Brutkiewicz
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

3.  The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS.

Authors:  Beate Fuchs; Jürgen Schiller; Ulf Wagner; Holm Häntzschel; Klaus Arnold
Journal:  Clin Biochem       Date:  2005-10       Impact factor: 3.281

4.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.

Authors:  David H Chang; Nancy Liu; Virginia Klimek; Hani Hassoun; Amitabha Mazumder; Stephen D Nimer; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

5.  CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver.

Authors:  Tony Kenna; Margaret O'Brien; Andrew E Hogan; Mark A Exley; Steven A Porcelli; John E Hegarty; Cliona O'Farrelly; Derek G Doherty
Journal:  Cancer Immunol Immunother       Date:  2006-08-22       Impact factor: 6.968

6.  Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.

Authors:  Radek Spisek; Anjli Kukreja; Lin-Chi Chen; Phillip Matthews; Amitabha Mazumder; David Vesole; Sundar Jagannath; Henry A Zebroski; Andrew J G Simpson; Gerd Ritter; Brian Durie; John Crowley; John D Shaughnessy; Matthew J Scanlan; Ali O Gure; Bart Barlogie; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

7.  A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.

Authors:  Masaki Terabe; Jeremy Swann; Elena Ambrosino; Pratima Sinha; Shun Takaku; Yoshihiro Hayakawa; Dale I Godfrey; Suzanne Ostrand-Rosenberg; Mark J Smyth; Jay A Berzofsky
Journal:  J Exp Med       Date:  2005-12-19       Impact factor: 14.307

8.  Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.

Authors:  Caroline Aspord; Alexander Pedroza-Gonzalez; Mike Gallegos; Sasha Tindle; Elizabeth C Burton; Dan Su; Florentina Marches; Jacques Banchereau; A Karolina Palucka
Journal:  J Exp Med       Date:  2007-04-16       Impact factor: 14.307

9.  Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program.

Authors:  Kavita M Dhodapkar; Devi Banerjee; John Connolly; Anjli Kukreja; Elyana Matayeva; Maria Concetta Veri; Jeffrey V Ravetch; Ralph M Steinman; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

10.  The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.

Authors:  Corinna McCarthy; Dawn Shepherd; Sebastian Fleire; Victoria S Stronge; Michael Koch; Petr A Illarionov; Giovanna Bossi; Mariolina Salio; Galit Denkberg; Faye Reddington; Andrea Tarlton; B Gopal Reddy; Richard R Schmidt; Yoram Reiter; Gillian M Griffiths; P Anton van der Merwe; Gurdyal S Besra; E Yvonne Jones; Facundo D Batista; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

View more
  88 in total

1.  Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid.

Authors:  Philomena Arrenberg; Ramesh Halder; Yang Dai; Igor Maricic; Vipin Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 3.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

4.  Self-glycerophospholipids activate murine phospholipid-reactive T cells and inhibit iNKT cell activation by competing with ligands for CD1d loading.

Authors:  Ramesh Chandra Halder; Cynthia Tran; Priti Prasad; Jing Wang; Dhiraj Nallapothula; Tatsuya Ishikawa; Meiying Wang; Dirk M Zajonc; Ram Raj Singh
Journal:  Eur J Immunol       Date:  2018-12-18       Impact factor: 5.532

5.  Non-classical natural killer T cells modulate plasmid DNA vaccine antigen expression and vaccine-elicited immune responses by MCP-1 secretion after interaction with a beta2-microglobulin-independent CD1d.

Authors:  Ralf Geiben-Lynn; John R Greenland; Kwesi Frimpong-Boateng; Norman L Letvin
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

Review 6.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

7.  Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation.

Authors:  Shiny Nair; Chandra Sekhar Boddupalli; Rakesh Verma; Jun Liu; Ruhua Yang; Gregory M Pastores; Pramod K Mistry; Madhav V Dhodapkar
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

8.  Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.

Authors:  Jie Zhao; Xiufang Weng; Sreya Bagchi; Chyung-Ru Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 9.  Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Authors:  Philomena Arrenberg; Ramesh Halder; Vipin Kumar
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

Review 10.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.